Skip to main content
. 2023 Jun 11;12(12):3970. doi: 10.3390/jcm12123970

Figure 2.

Figure 2

Flowchart showing the potential use of sST2 in chronic heart failure. sST2 is a biomarker of myocardial fibrosis and ventricular remodeling. It could be used in the risk stratification process in addition to NPs and hs-cTnT, as they reflect diverse biologic pathways in HF. Serial testing of sST2 could be helpful in identifying patients who most benefit from anti-remodeling therapies.